Compare ASIC & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASIC | SPTX |
|---|---|---|
| Founded | 2018 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2025 | 2026 |
| Metric | ASIC | SPTX |
|---|---|---|
| Price | $24.36 | $19.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $28.40 | ★ $37.13 |
| AVG Volume (30 Days) | 73.7K | ★ 249.2K |
| Earning Date | 10-21-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.44 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $424,339,000.00 | N/A |
| Revenue This Year | $24.89 | N/A |
| Revenue Next Year | $22.34 | N/A |
| P/E Ratio | $16.69 | ★ N/A |
| Revenue Growth | ★ 23.41 | N/A |
| 52 Week Low | $16.73 | $15.79 |
| 52 Week High | $29.00 | $28.38 |
| Indicator | ASIC | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 43.36 |
| Support Level | $23.36 | $18.79 |
| Resistance Level | $25.62 | $22.57 |
| Average True Range (ATR) | 0.84 | 1.47 |
| MACD | 0.08 | -0.09 |
| Stochastic Oscillator | 62.35 | 13.67 |
Ategrity Specialty Insurance Co Holdings is a specialty property and casualty insurance holding company focused on the excess and surplus market for small to medium-sized businesses (SMBs) across the United States. Operating through its subsidiaries, the company underwrites small and medium-sized commercial risks across selected industry verticals, including Retail, Real Estate, Hospitality, and Construction. Its operating model uses a technology-driven method to standardize, simplify, and, where appropriate, automate these transactions. The group distributes its products through licensed surplus lines brokers and wholesale agents.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.